Document is current
Any future updates will be listed below
-
Authors
Müller-Dott, Sophia https://orcid.org/0000-0002-9710-1865
Jaehnig, Eric J. https://orcid.org/0000-0001-9618-6011
Munchic, Khoi Pham
Jiang, Wen
Yaron-Barir, Tomer M.
Savage, Sara R.
Garrido-Rodriguez, Martin https://orcid.org/0000-0003-4125-5643
Johnson, Jared L. https://orcid.org/0000-0003-1802-6527
Lussana, Alessandro https://orcid.org/0000-0002-4733-0934
Petsalaki, Evangelia https://orcid.org/0000-0002-8294-2995
Lei, Jonathan T.
Dugourd, Aurelien
Krug, Karsten
Cantley, Lewis C. https://orcid.org/0000-0002-1298-7653
Mani, D. R. https://orcid.org/0000-0003-3914-133X
Zhang, Bing https://orcid.org/0000-0001-8676-2425
Saez-Rodriguez, Julio https://orcid.org/0000-0002-8552-8976
-
Funding
Funding for this research was provided by:
NIH R35
Proteogenomics Data Analysis Center
Cancer Prevention and Research Institute of Texas (RP220050)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (U24-CA271076)
Robert and Janice McNair Foundation (NA)
- License Information
-
More Information
Article History
Received: 28 June 2024
Accepted: 5 May 2025
First Online: 22 May 2025
Competing interests
: J.S.R. reports funding from GSK, Pfizer and Sanofi and fees/honoraria from Travere Therapeutics, Stadapharm, Astex, Pfizer, Owkin and Grunenthal. B.Z. reports funding from AstraZeneca and fees from Inotiv. L.C.C. is a founder and member of the board of directors of Agios Pharmaceuticals and is a founder and receives research support from Petra Pharmaceuticals, is listed as an inventor on a patent (WO2019232403A1, Weill Cornell Medicine) for combination therapy for PI3K-associated disease or disorder, and the identification of therapeutic interventions to improve response to PI3K inhibitors for cancer treatment, is a co-founder and shareholder in Faeth Therapeutics, has equity in and consults for Cell Signaling Technologies, Volastra, Larkspur and 1 Base Pharmaceuticals. and consults for Loxo-Lilly. J.L.J. has received consulting fees from Scorpion Therapeutics and Volastra Therapeutics. T.M.Y.-B. is a co-founder of DeStroke. The remaining authors declare no competing interests.
